ハラ　ツカサ   Hara Tsukasa   原　司    所属   医学研究科 医学研究科 (医学部医学科をご参照ください)    職種   特任助教
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Deciphering molecular consequences of the proprotein convertase 1/3 inhibition in macrophages for application in anti-tumour immunotherapy.
掲載誌名	正式名：Journal of biotechnology 略　 称：J Biotechnol ISSNコード：18734863/01681656
掲載区分	国外
巻・号・頁	282,pp.80-85
総ページ数	6
著者・共著者	Rodet Franck, Capuz Alice, Hara Tsukasa, van Meel Rinaldo, Duhamel Marie, Rose Mélanie, Raffo-Romero Antonella, Fournier Isabelle, Salzet Michel
発行年月	2018/09
概要	During tumour development, macrophages are recruited to the tumour site and orientated towards an anti-inflammatory phenotype. Due to their immunosuppressive function, tumour associated macrophages (TAMs) are recognized as major components in tumour progression. Changing these macrophages to a pro-inflammatory phenotype is thus extensively studied as a potential means for developing novel anti-tumour therapy. In this context, we found that the Proprotein convertase 1/3 (PC1/3) is a relevant target. Proteomic analysis reveals that PC1/3 knockdown (KD) macrophages present all the characteristic of activated pro-inflammatory macrophages. Moreover, in PC1/3 KD macrophages, TLR4 and TLR9 signaling pathways can be enhanced leading to the secretion of pro-inflammatory factors and anti-tumour factors. To develop an efficient anti-tumour immunotherapy, we may (i) target TAMs directly inside the tumour site for PC1/3 inhibition and TLR activation and used them as "Trojan macrophages" or (ii) directly take advantage of PC1/3 inhibited macrophages and use them as "drone macrophages" by activating them "at distance" with a TLR ligand. Therefore, PC1/3 inhibited macrophages constitute an innovative cell therapy to treat tumours efficiently.
DOI	10.1016/j.jbiotec.2018.07.002
PMID	29990570